Table 6.
Kaplan-Meier survival estimates
| Variable | No. of cases | DFS P value | OS P value |
| Sex (n, %) | 0.668 | 0.448 | |
| Male | 160 (69.3) | ||
| Female | 71 (30.7) | ||
| Age (year) | 0.518 | 0.688 | |
| < 60 | 111 (48.1) | ||
| ≥ 60 | 120 (51.9) | ||
| ASA (n, %) | 0.691 | 0.658 | |
| 1 | 7 (3) | ||
| 2 | 178 (77) | ||
| 3 | 46 (19.9) | ||
| BMI (kg/m2) | 0.759 | 0.587 | |
| < 25 | 149 (64.5) | ||
| ≥ 25 | 82 (35.5) | ||
| Interval time, w (%) | 0.002 | 0.259 | |
| ≤ 9 wk | 139 (60.2) | ||
| > 9 wk | 92 (39.8) | ||
| cT, n (%) | 0.343 | 0.483 | |
| 2 | 2 (0.9) | ||
| 3 | 180 (77.9) | ||
| 4 | 49 (21.2) | ||
| cN, n (%) | 0.059 | 0.084 | |
| 0 | 62 (26.8) | ||
| 1 | 119 (51.5) | ||
| 2 | 50 (21.6) | ||
| ypT, n (%) | < 0.001 | 0.001 | |
| 0 | 40 (17.3) | ||
| 1 | 5 (2.2) | ||
| 2 | 48 (20.8) | ||
| 3 | 121 (52.4) | ||
| 4 | 17 (7.4) | ||
| ypN, n (%) | 0.001 | 0.185 | |
| 0 | 128 (55.4) | ||
| 1 | 74 (32) | ||
| 2 | 29 (12.6) | ||
| Surgical procedure | 0.109 | 0.464 | |
| Miles (n, %) | 100 (43.3) | ||
| Dixon (n, %) | 113 (48.9) | ||
| Hartmann (n, %) | 18 (7.8) | ||
| Postoperative complications, n (%) | 0.265 | 0.043 | |
| Yes | 12 (5.2) | ||
| No | 219 (94.8) | ||
| Degree of differentiation, n (%) | 0.094 | 0.183 | |
| Low and low-moderate grades | 32 (13.9) | ||
| Moderate, moderate-high, and high grades | 193 (83.5) | ||
| Signet-ring and mucinous adenocarcinoma | 6 (2.6) | ||
| Preoperative concurrent chemotherapy regimen, n (%) | 0.357 | 0.533 | |
| Capecitabine + oxaliplatin | 71 (30.7) | ||
| Capecitabine oral | 145 (62.8) | ||
| Oxaliplatin union | 15 (6.5) |
BMI: Body mass index; ASA: American Society of Anesthesiologists; DFS: Disease-free survival; OS: Overall survival.